Has Shawn Kwatra, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,086,175 in general payments to Shawn Kwatra, MD across 502 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shawn Kwatra, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shawn Kwatra, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shawn Kwatra, MD

Dermatology · Baltimore, MDNPI 1205191400

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.0%), grants and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Sanofi at 41.8% of the total. Reporting peaked in 2023 at $408,996 and has fallen 74.2% since, to $105,485 in 2025. Among dermatology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,086,175in general payments, 2019–2025

Across 502 payments — averaging $2163.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$454K
Regeneron$281K
Galderma Laboratories, L.p.$76K
Regeneron Healthcare Solutions, Inc.$54K
Eli Lilly$38K
Pfizer$33K
plus $149K from 18 others

$1,345,651in research payments, 2019–2025

Across 330 payments — averaging $4077.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$838K
Incyte Corporation$240K
Sanofi US Services Inc.$123K
Regeneron$86K
Galderma Laboratories, L.p.$30K
Sanofi$18K
plus $12K from 3 others

What the payments were for

Consulting fees$543,20950%
Speaking & faculty fees$184,98517%
Grants$250,00023%
Travel & lodging$94,8989%
Food & beverage$12,9481%
Education$1350%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	137	$454,135
Regeneron	48	$280,696
Galderma Laboratories, L.p.	49	$76,426
Regeneron Healthcare Solutions, Inc.	52	$54,463
Eli Lilly	30	$37,534
Pfizer	29	$33,460
Sanofi-aventis U.S. LLC	9	$33,428
AbbVie(2 entities)	46	$31,878
Incyte Corporation	29	$20,165
Galderma Research & Development, LLC	4	$12,750
Amgen	9	$10,943
Novartis	6	$8,945
Arcutis Biotherapeutics, Inc.	12	$8,514
Janssen Scientific Affairs, LLC	3	$5,113
LEO Pharma Inc.	5	$4,701
Lilly USA, LLC	12	$4,254
Janssen Global Services, LLC	2	$2,975
Dermavant Sciences, Inc.	3	$2,819
E.r. Squibb & Sons, L.L.C.	1	$2,170
Sun Pharmaceutical Industries Inc.	6	$245
Ortho Dermatologics, A Division Of Bausch Health US, LLC	3	$244
Johnson & Johnson	4	$199
Boehringer Ingelheim	2	$88
Organon	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$359,405
EBGLYSS$18,000
Rinvoq$10,915
EUCRISA$10,436
CIBINQO$9,746
Skyrizi$8,778
Otezla$7,242
Tremfya$5,263
VTAMA$2,750
COSENTYX$2,500
ADBRY$2,280
ZORYVE$886
NEMLUVIO$259
OPZELURA$247
DYSPORT$158
AKLIEF$106

How this compares

$1,086,175 in reported general payments places this provider in the 95th percentile of 306 dermatology providers in Maryland.

See all dermatology providers in Maryland →

Medicare billing

Part B allowed, 2024

$63,019

Medicare patients

254

Services billed

714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clindamycin Phosphate	11	$623
Ketoconazole	15	$597
Triamcinolone Acetonide	21	$221

Paid to pharmacies, not to this prescriber.

Other dermatology in Baltimore

Crystal AguhBaltimore$142K
Tamia Harris-TryonBaltimore$128K
Elizabeth TanziBaltimore$59K
Luis GarzaBaltimore$44K
Sewon KangBaltimore$44K
Sima RozatiBaltimore$35K
Larry GastonBaltimore$27K
Janet LinBaltimore$23K
Julie DeutschBaltimore$10K
Benjamin LockshinSilver Spring$4M

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →